Our analysis predicted CXCR4 as a potential target for DLBCL treatment, which may serve as an inhibitor both on BCR signaling and nuclear export warranting further investigation in clinical trials. The gene discussed is CXCR4; the disease is diffuse large B-cell lymphoma.